JAAD supplemental material - Response to systemic therapies in granulomatous cheilitis: retrospective multicenter series of 61 patients

Supplemental Material Supplemental material Mendeley Supplemental Table 1. Case review of systemic therapies in CG. Mendeley Supplemental Table 2. Modalities and responses to systemic therapies in the whole study population and by underlying disease. Response rates (proportion of responders including CR and PR), CR rates, duration of therapy, duration of response and relapse rates were assessed for each systemic therapy modality. Only therapies that had been assessed in at least 3 patients are provided. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; IFX, infliximab; ADA, adalimumab; CR, complete responses; NA, not applicable. Mendeley Supplemental Figure 1. Responses to systemic therapies in patients with Miescher’s macrocheilitis (n=38). Best response (non-response [NR], complete response [CR] or partial response [PR]) is indicated. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; MTX, methotrexate; THD, thalidomide; SZP, salazopyrine; IFX, infliximab; ADA, adalimumab; RITUX, rituximab Mendeley Supplemental Figure 2. Responses to systemic therapies in patients with Melkersson-Rosenthal syndrome (n=9, panel A), Crohn’s disease (n=10, panel B) and sarcoidosis (n=4, panel C). Best response (non-response [NR], complete response [CR] or partial response [PR]) is indicated. CFZ, clofazimine; HCQ, hydroxychloroquine; CS, corticosteroids; MTZ, metronidazole; MTX, methotrexate; THD, thalidomide; AZA, azathioprine; ASA, 5-aminosalicylic acid; CYS, cyclosporine; IFX, infliximab; ADA, adalimumab; UST, ustekinumab; GOLI, golimumab; VEDO, vedolizumab. Mendeley Supplemental Figure 3. Cumulative proportion of complete response over time. The Kaplan-Meier cumulative incidence curve was constructed to assess the proportion of patients with complete resolution of GC over time. (XL-Stat-Life, Addinsoft, Paris, France).补充材料 Mendeley 补充表1：CG患者全身治疗病例回顾。 Mendeley 补充表2：全研究人群及按基础疾病分层的亚组的全身治疗方式与治疗应答情况。针对每种全身治疗方式，评估了应答率（包含完全缓解[CR, complete responses]与部分缓解[PR]的应答者占比）、完全缓解率、治疗持续时间、应答持续时间及复发率。仅纳入至少在3例患者中完成评估的治疗方案。 缩写释义：氯法齐明（CFZ, clofazimine）；羟氯喹（HCQ, hydroxychloroquine）；糖皮质激素（CS, corticosteroids）；甲硝唑（MTZ, metronidazole）；英夫利昔单抗（IFX, infliximab）；阿达木单抗（ADA, adalimumab）；完全缓解（CR, complete responses）；不适用（NA, not applicable）。 Mendeley 补充图1：米舍尔巨唇炎（Miescher’s macrocheilitis，n=38）患者的全身治疗应答情况。图示最佳应答结局（无应答[NR, non-response]、完全缓解[CR]或部分缓解[PR]）。 缩写释义：氯法齐明（CFZ）；羟氯喹（HCQ）；糖皮质激素（CS）；甲硝唑（MTZ）；甲氨蝶呤（MTX, methotrexate）；沙利度胺（THD, thalidomide）；柳氮磺吡啶（SZP, salazopyrine）；英夫利昔单抗（IFX）；阿达木单抗（ADA）；利妥昔单抗（RITUX, rituximab）。 Mendeley 补充图2：梅-罗综合征（Melkersson-Rosenthal syndrome，n=9，图A）、克罗恩病（Crohn’s disease，n=10，图B）及结节病（sarcoidosis，n=4，图C）患者的全身治疗应答情况。图示最佳应答结局（无应答[NR]、完全缓解[CR]或部分缓解[PR]）。 缩写释义：氯法齐明（CFZ）；羟氯喹（HCQ）；糖皮质激素（CS）；甲硝唑（MTZ）；甲氨蝶呤（MTX）；沙利度胺（THD）；硫唑嘌呤（AZA, azathioprine）；5-氨基水杨酸（ASA, 5-aminosalicylic acid）；环孢素（CYS, cyclosporine）；英夫利昔单抗（IFX）；阿达木单抗（ADA）；乌司奴单抗（UST, ustekinumab）；戈利木单抗（GOLI, golimumab）；维多珠单抗（VEDO, vedolizumab）。 Mendeley 补充图3：完全缓解的累积比例随时间变化曲线。本研究构建了Kaplan-Meier累积发病率曲线，以评估GC患者症状随时间完全缓解的比例。（分析软件：XL-Stat-Life，Addinsoft公司，法国巴黎）。